Engineered Bacterial Ligand From Streptococcus pneumoniae on Macroporous Resins for Selective Affinity Capture of Secretory IgA
Biotechnology and Bioengineering · 2026-06 · 123 (6) · 1531-1543
DOI: 10.1002/bit.70189 ↗At a glance
Journal article in Biotechnology and Bioengineering, published online on 2026-03-08. Written by David Scheich and 8 co-authors. Institution: Department of Biotechnology and Food Science, Institute of Bioprocess Science and Engineering, BOKU University, Vienna, Austria. Major MEDLINE topics: Chromatography, Affinity, Streptococcus pneumoniae, Bacterial Proteins, Immunoglobulin A, Secretory. 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: Austrian Science Fund, Research Foundation Flanders - FWO.
Abstract (original language)
Secretory immunoglobulin A (sIgA) is a promising emerging biopharmaceutical candidate, but it currently lacks a standardized platform for purification. To address this, a novel affinity chromatography resin was developed by immobilizing protein variants of the Streptococcus pneumoniae surface protein, SpsA, as an affinity ligand. SpsA targets the secretory component of sIgA, which increases selectivity and minimizes co‐purification of product‐related impurities. Directed attachment between a single cysteine residue and macroporous epoxy‐activated supports was employed as an immobilization strategy. Ligand orientation on the resin surface is of utmost importance, as the initial SpsA variant was unable to bind sIgA after immobilization. The cysteine residue was subsequently relocated from the C‐terminus to either the N‐terminus or loop region of the ligand, resulting in a functional resin. 177 nmol SpsA/mL resin were immobilized on the agarose‐based resin, resulting in an equilibrium binding capacity of 9.1 mg sIgA/mL resin. SpsA resin was able to selectively purify sIgA from cell culture supernatant under dynamic conditions with free secretory component as the only product‐related impurity. SpsA‐based affinity chromatography may enable a scalable purification process for sIgA through an appropriate resin structure and improved selectivity.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biotechnology and Food Science, Institute of Bioprocess Science and Engineering, BOKU University, Vienna, Austria.
- Icosagen Cell Factory OÜ, Tartu, Estonia.
- Department of Chemical Engineering, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
- Acib - Austrian Centre of Industrial Biotechnology, Vienna, Austria.
ORCID profiles: David Scheich, Sebastiaan Eeltink, Rainer Hahn, Alois Jungbauer, Nico Lingg
Funding
- Austrian Science Fund
- Research Foundation Flanders - FWO
Cite
APA
Scheich, D., Männik, A., Meikar, O., Teyra, J., Kibena, L., Eeltink, S., Hahn, R., Jungbauer, A., & Lingg, N. (2026). Engineered Bacterial Ligand From Streptococcus pneumoniae on Macroporous Resins for Selective Affinity Capture of Secretory IgA. Biotechnology and Bioengineering, 123(6), 1531-1543. https://doi.org/10.1002/bit.70189
Vancouver
Scheich D, Männik A, Meikar O, Teyra J, Kibena L, Eeltink S, et al. Engineered Bacterial Ligand From Streptococcus pneumoniae on Macroporous Resins for Selective Affinity Capture of Secretory IgA. Biotechnology and Bioengineering. 2026;123(6):1531-1543. doi:10.1002/bit.70189
BibTeX
@article{Scheich2026,
author = {Scheich, David and Männik, Andres and Meikar, Oliver and Teyra, Joan and Kibena, Laura and Eeltink, Sebastiaan and Hahn, Rainer and Jungbauer, Alois and Lingg, Nico},
title = {Engineered Bacterial Ligand From Streptococcus pneumoniae on Macroporous Resins for Selective Affinity Capture of Secretory IgA},
journal = {Biotechnology and Bioengineering},
year = {2026},
volume = {123},
number = {6},
pages = {1531--1543},
doi = {10.1002/bit.70189}
}
EUVIMED